drugset / Trial / NCT03554707
SGT-53 in Children With Recurrent or Progressive CNS Malignancies
NaSingle-groupOpen-labelTreatment
Summary
An early phase 1 for pediatric patients with recurrent or progressive CNS malignancies
Timeline
- Start
- 2022-06-01
- Primary completion
- 2022-06-01
- Completion
- 2022-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SGT-53 | Other / unclassified | 2.1 mg/m2 | Intravenous |
| Subject | SGT-53 | Other / unclassified | 2.8 mg/m2 | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Background | Irinotecan | Small molecule | 50 mg/m2 | Intravenous |
| Background | Temozolomide | Small molecule | 100 mg/m2 | Oral |